Oral delivery of siRNA and antisense oligonucleotides

Journal of Drug Targeting

Volumn 17, Issue 7, 2009, Pages 491-495

  Akhtar, Saghir ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

Author keywords

Gene silencing; GIT; Gut; M cells; Oligodeoxynucleotides; Oral drug delivery; Peyers patches; Short interfering RNA

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BETA 1,3 GLUCAN; SMALL INTERFERING RNA;

DRUG TRANSPORT; DRUG UPTAKE; GENE SILENCING; HUMAN; INTESTINE LYMPHATIC TISSUE; NONHUMAN; NOTE; PEYER PATCH; PRIORITY JOURNAL; ANIMAL; ARTICLE; DRUG DELIVERY SYSTEM; GENE TRANSFER; METABOLISM; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANIMALS; DRUG DELIVERY SYSTEMS; GENE SILENCING; GENE TRANSFER TECHNIQUES; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; PEYER'S PATCHES; RNA, SMALL INTERFERING;

EID: 70349784215     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.1080/10611860903057674     Document Type: Note

References (39)

1. Agrawal S, Zhang XS, Lu ZH, Zhao H, Tamburin JM, Yan YM, Cai HY, Diasio RB, Habus I, Jiang ZW, Iyer RP, Yu D, Zhang RW. (1995). Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral-administration. Biochem Pharmacol, 50(4), 571-576.
2. Aigner A. (2008). Cellular delivery in vivo of siRNA-based therapeutics. Curr Pharm Des, 14(34), 3603-3619. [Review]
3. Akhtar S. (2006). Non-viral vectors for gene therapy: beyond delivery. Gene Ther, 13, 739-740.
4. Akhtar S, Benter IF. (2007a, December). Nonviral delivery of synthetic siRNAs in vivo. J Clin Invest, 117(12), 3623-3632.
5. Akhtar S, Benter I. (2007b, March 30). Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNAmediated gene silencing activity and specificity. Adv Drug Deliv Rev, 59(2-3), 164-182.
6. Akhtar S, Hughes MD, Khan A, Bibby M, Hussain M, Nawaz Q, Double J, Sayyed P. (2000). The delivery of antisense therapeutics. Adv Drug Deliv Rev, 44(1), 3-21.
7. Aouadi M, Tesz GJ, Nicoloro SM, Wang M, Chouinard M, Soto E, Ostroff GR, Czech MP. (2009, April 30). Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation. Nature, 458(7242), 1180-1184.
8. Beale G, Hollins AJ, Benboubetra M, Sohail M, Fox SP, Benter I, Akhtar S. (2003, August). Gene silencing nucleic acids designed by scanning arrays: anti-EGFR activity of siRNA, ribozyme and DNA enzymes targeting a single hybridization-accessible region using the same delivery system. J Drug Target, 11(7), 449-456.
9. Bertrand JR, Pottier M, Vekris A, Opolon P, Maksimenko A, Malvy C. (2002, August 30). Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochem Biophys Res Commun, 296(4), 1000-1004.
10. Corr SC, Gahan CC, Hill C. (2008, January). M-cells: origin, morphology and role in mucosal immunity and microbial pathogenesis. FEMS Immunol Med Microbiol, 52(1), 2-12.
11. Costanotto D, Rossi JJ. (2009). The promises and pitfalls of RNA- interference-based therapeutics. Nature, 457(7228), 426-433.
12. Fattal E, Bochot A. (2008, December 8). State of the art and perspectives for the delivery of antisense oligonucleotides and siRNA by polymeric nanocarriers. Int J Pharm, 364(2), 237-248.
13. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. (1998). Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature, 391, 806-811. (Pubitemid 28099681)
14. Florence AT. (2004, February). Issues in oral nanoparticle drug carrier uptake and targeting. J Drug Target, 12(2), 65-70. [Review]
15. González Ferreiro M, Tillman LG, Hardee G, Bodmeier R. Alginate/ poly-L-lysine microparticles for the intestinal delivery of antisense oligonucleotides. Pharm Res. 2002 Jun;19(6):755-64.
16. Gilmore IR, Fox SP, Hollins AJ, Akhtar S. Delivery strategies for siRNAmediated gene silencing. Curr Drug Deliv. 2006 Apr;3(2):147-155 [Review]
17. Hollins AJ, Omidi Y, Benter IF, Akhtar S. (2007, January). Toxicogenomics of drug delivery systems: exploiting delivery system-induced changes in target gene expression to enhance siRNA activity. J Drug Target, 15(1), 83-88.
18. Hughes MD, Hussain M, Nawaz Q, Sayyed P, Akhtar S. (2001). The cellular delivery of antisense oligonucleotides and ribozymes. Drug Discov Today, 6(6), 303-315.
19. Hussain N, Jaitley V, Florence AT. (2001, August 23). Recent advances in the understanding of uptake of microparticulates across the gastrointestinal lymphatics. Adv Drug Deliv Rev, 50(1-2), 107-142.
20. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, Maclachlan I. (2005). Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol, 23(4), 457-462.
21. Juliano R, Alam MR, Dixit V, Kang H. (2008, July). Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res, 36(12), 4158-4171.
22. Kabanov AV. (2006, December 30). Polymer genomics: an insight into pharmacology and toxicology of nanomedicines. Adv Drug Deliv Rev, 58(15), 1597-1621.
23. Khan A, Benboubetra M, Sayyed PZ, Ng KW, Fox S, Beck G, Benter IF, Akhtar S. (2004). Sustained polymeric delivery of gene silencing antisense ODNs, siRNA, DNAzymes and ribozymes: in vitro and in vivo studies. J Drug Target, 12(6), 393-404.
24. Kindrachuk J, Potter J, Wilson HL, Griebel P, Babiuk LA, Napper S. (2008, June). Activation and regulation of toll-like receptor 9: CpGs and beyond. Mini Rev Med Chem, 8(6), 590-600.
25. Kleinman ME, Yamada K, Takeda A, Chandrasekaran V, Nozaki M, Baffi JZ, Albuquerque RJ, Yamasaki S, Itaya M, Pan Y, Appukuttan B, Gibbs D, Yang Z, Karikó K, Ambati BK, Wilgus TA, DiPietro LA, Sakurai E, Zhang K, Smith JR, Taylor EW, Ambati J. (2008, April 3). Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature, 452(7187), 591-597.
26. Krishnamachari Y, Salem AK. (2009, March). Innovative strategies for co-delivering antigens and CpG oligonucleotides. Adv Drug Deliv Rev, 61(3), 205-217.
27. Kurreck J. (2009). RNA interference: from basic research to therapeutic applications. Angew Chem Int Ed Engl, 48(8), 1378-1398.
28. McMinn LH, Hodges GM, Carr KE. Gastrointestinal uptake and translocation of microparticles in the streptozotocin-diabetic rat. J Anat. 1996 Dec;189 ( Pt 3):553-559
29. Omidi Y, Hollins AJ, Benboubetra M, Drayton R, Benter IF, Akhtar S. (2003, July). Toxicogenomics of non-viral vectors for gene therapy: a microarray study of lipofectin- and oligofectamineinduced gene expression changes in human epithelial cells. J Drug Target, 11(6), 311-323.
30. Omidi Y, Hollins AJ, Drayton RM, Akhtar S. (2005, August). Polypropylenimine dendrimer-induced gene expression changes: the effect of complexation with DNA, dendrimer generation and cell type. J Drug Target, 13(7), 431-443.
31. Raoof AA, Ramtoola Z, McKenna B, Yu RZ, Hardee G, Geary RS. (2002, November). Effect of sodium caprate on the intestinal absorption of two modified antisense oligonucleotides in pigs. Eur J Pharm Sci, 17(3), 131-138.
32. Raoof AA, Chiu P, Ramtoola Z, Cumming IK, Teng C, Weinbach SP, Hardee GE, Levin AA, Geary RS. (2004, June). Oral bioavailability and multiple dose tolerability of an antisense oligonucleotide tablet formulated with sodium caprate. J Pharm Sci, 93(6), 1431-1439.
33. Reischl D, Zimmer A. (2009, March). Drug delivery of siRNA therapeutics: potentials and limits of nanosystems. Nanomedicine, 5(1), 8-20.
34. Robbins M, Judge A, Maclachlan I. (2009, May 14). siRNA and innate immunity. Oligonucleotides. [Epub ahead of print]
35. Sioud M. (2009). Deciphering the code of innate immunity recognition of siRNAs. Methods Mol Biol, 487, 41-59.
36. Tillman LG, Geary RS, Hardee GE. (2008). Oral delivery of antisense oligonucleotides in man. J Pharm Sci, 97(1), 225-236.
37. Vlassov VV, Karamyshev VN, Yakubov LA. (1993). Penetration of oligonucleotides into mouse organism through mucosa and skin. FEBS Lett, 327(3), 271-274.
38. Whitehead KA, Langer R, Anderson DG. (2009, February). Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov, 8(2), 129-138. [Review]
39. Woodrow KA, Cu Y, Booth CJ, Saucier-Sawyer JK, Wood MJ, Mark Saltzman W. (2009, May 3). Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA. Nat Mater. [Epub ahead of print]